NEC baby formula.
Necrotizing enterocolitis litigation.
Federal multi-district litigation alleging that Abbott's Similac and Mead Johnson's Enfamil cow's milk-based infant formulas caused necrotizing enterocolitis in premature infants. State-court verdicts have totaled more than half a billion dollars, while the federal MDL faces causation headwinds.
The plaintiff theory.
The product. The injury.
The NEC MDL consolidates claims against Abbott Laboratories (Similac) and Mead Johnson (Enfamil) brought by families of premature infants who developed necrotizing enterocolitis — a severe, often fatal gastrointestinal disease that primarily affects preterm newborns. Plaintiffs allege that cow's milk-based infant formulas marketed for premature infants substantially increase the risk of NEC compared to human milk, and that the manufacturers failed to warn families and NICU clinicians of that increased risk.
The scientific basis is well-established. Multiple meta-analyses, including expert work prepared for the MDL, have found a statistically significant increased risk of NEC in formula-fed preterm infants compared to those fed human milk. The American Academy of Pediatrics has recommended human milk for premature infants since 2012; the U.S. Surgeon General linked formula feeding to higher NEC rates in 2011. The litigation focuses on the gap between this clinical consensus and the warnings provided to families.
NEC disproportionately affects African-American premature infants. Recent epidemiological research from Emory University underscores the racial disparity in NEC incidence and mortality, which is reflected in the demographic profile of the litigation's plaintiff population.
Procedural posture.
Mixed federal/state record.
The federal MDL has produced a difficult record for plaintiffs. Judge Pallmeyer granted summary judgment for the defense in the first three federal bellwethers — Mar v. Abbott (May 2025), Diggs v. Abbott (July 2025), and a third in October 2025 — primarily on causation grounds tied to the alternative-formulation feasibility analysis. The fourth bellwether, Inman v. Mead Johnson, is scheduled for July 6, 2026, and a recent ruling preserving plaintiffs' epidemiology expert testimony from Dr. Logan Spector has restored some plaintiff momentum heading into that trial.
The state-court record has been the opposite. An Illinois jury awarded $60 million against Mead Johnson in March 2024. A Missouri jury awarded $495 million against Abbott in July 2024. While a subsequent Missouri defense verdict was vacated for trial misconduct in March 2025, the state-court track has consistently produced the favorable plaintiff outcomes that have not yet emerged from the federal MDL.
Acquisition. Screening.
Retention.
NEC intake requires documentation that the infant was born premature (typically before 37 weeks gestation), was fed cow's milk-based Similac or Enfamil products in a NICU setting, and developed NEC within a clinically plausible timeframe (typically two to six weeks after first formula exposure). Eligibility is narrower than many mass-tort dockets — the population is defined, the medical records are concentrated in NICU settings, and venue strategy materially affects case value given the federal/state divergence. We have built docket-specific intake protocols for the medical-record retrieval this docket requires.
Acquisition runs across paid social, paid search, and connected TV, with creative built specifically for this docket and compliance review on every iteration. Every claimant flows through our multi-vendor fraud-detection suite — Anura, CHEQ, ActiveProspect, TrustedForm, Blacklist Alliance, and Plaid — before reaching the partner firm. Retained cases land directly in the firm's case management system in real time.
For partner firms holding NEC dockets, we provide standing operational reporting on retained cases delivered, cost per qualified retention, and case-tier mix against your screening criteria. Strategy sessions cover docket-portfolio decisions: how to weight federal MDL versus state-court venue selection, which case profiles align with the cases that have produced large state verdicts, and how the Inman bellwether outcome shifts retention thresholds.
Start a conversation.
Speak with our team.
A LeadClient case-acquisition strategist will reach out to talk through your docket.